BHT-3009: Additional Phase IIb data

Bayhill reported data from a subgroup of 58 MS patients with baseline cerebral spinal fluid (CSF) IgG levels >=2.5 mg/dL who were enrolled in the company's previously reported Phase IIb trial in 289 p...